Cited by 447Acute Myeloid Leukemia ResearchCancer Genomics and DiagnosticsChronic Myeloid Leukemia Treatments

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia

Open access

McMahon, Christine M., Ferng, Timothy, Canaani, Jonathan, Wang, Eunice S., Morrissette, Jennifer J.D., Eastburn, Dennis J., Pellegrino, Maurizio, Durruthy-Durruthy, Robert, Watt, Christopher D., Asthana, Saurabh, Lasater, Elisabeth A., DeFilippis, RosaAnna, Peretz, Cheryl A.C., McGary, Lisa H.F., Deihimi, Safoora, Logan, Aaron C., Luger, Selina M., Shah, Neil P., Carroll, Martin, Smith, Catherine C., Perl, Alexander E.·2019·Cancer Discovery

DOI 10.1158/2159-8290.cd-18-1453PMC PMC11994087

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clinical efficacy in relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however, gilteritinib is not curative, and response duration is limited by the development of secondary resistance. To evaluate resistance mechanisms, we analyzed baseline and progression samples from patients treated on clinical trials of gilteritinib. Targeted next-generation sequencing at the time of AML progression on gilteritinib identified treatment-emergent mutations that activate RAS/MAPK pathway signaling, most commonly in NRAS or KRAS. Less frequently, secondary FLT3-F691L gatekeeper mutations or BCR–ABL1 fusions were identified at progression. Single-cell targeted DNA sequencing revealed diverse patterns of clonal selection and evolution in response to FLT3 inhibition, including the emergence of RAS mutations in FLT3-mutated subclones, the expansion of alternative wild-type FLT3 subclones, or both patterns simultaneously. These data illustrate dynamic and complex changes in clonal architecture underlying response and resistance to mutation-selective tyrosine kinase inhibitor therapy in AML. Significance: Comprehensive serial genotyping of AML specimens from patients treated with the selective FLT3 inhibitor gilteritinib demonstrates that complex, heterogeneous patterns of clonal selection and evolution mediate clinical resistance to tyrosine kinase inhibition in FLT3-mutated AML. Our data support the development of combinatorial targeted therapeutic approaches for advanced AML. See related commentary by Wei and Roberts, p. 998. This article is highlighted in the In This Issue feature, p. 983

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-18-1453

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Clonal Evolution of Tumor Cell Populations: Acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression.
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
Grimwade, D. J., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., & Burnett, A. K. (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,936
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611
The origin and evolution of mutations in acute myeloid leukemia
Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.023 · Cited by 1,575
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Yamamoto, Y. (2001) · Blood · doi:10.1182/blood.v97.8.2434 · Cited by 1,152
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm
Fröhling, S., Schlenk, R. F., Breitruck, J., Benner, A., Kreitmeier, S., Tobis, K., Döhner, H., & Döhner, K. (2002) · Blood · doi:10.1182/blood-2002-05-1440 · Cited by 873
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Smith, C. C., Wang, Q., Chin, C.-S., Salerno, S. N., Damon, L. E., Levis, M. J., Perl, A. E., Travers, K. J., Wang, S., Hunt, J. P., et al. (2012) · Nature · doi:10.1038/nature11016 · Cited by 738
Self-citation

Show all 35 references

Research works printed but not linked: 1

Cortes, 2018, Quizartinib significantly prolongs overall survival in patients with FLT3-internal tandem duplication–mutated relapsed/refractory AML in the phase 3, randomized, controlled QuANTUM-R trial [abstract]

Sorted by citations

Items 201–300 of 447

Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib
Wang, P., Zhang, Y., Xiang, R., Yang, J., Xu, Y., Deng, T., Zhou, W., Wang, C., Xiao, X., & Wang, S. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-1534 · Cited by 12
FLT3 Inhibition in Acute Myeloid Leukaemia – Current Knowledge and Future Prospects
Hogan, F., Williams, V. L., & Knapper, S. (2020) · Current Cancer Drug Targets · doi:10.2174/1570163817666200518075820 · Cited by 12
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial
Ayala, R. M., Rapado, I., Onecha, E., Martínez‐Cuadrón, D., Carreño‐Tarragona, G., Bergua, J., Vives, S., Algarra, J. L., Tormo, M., Martı́nez, P., et al. (2021) · Cancers · doi:10.3390/cancers13102458 · Cited by 12
Somatic variant analysis suite: copy number variation clonal visualization online platform for large-scale single-cell genomics
Chen, L., Qing, Y., Li, R., Li, C., Li, H., Feng, X., & Li, S. C. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab452 · Cited by 12
The TLK-ASF1 histone chaperone pathway plays a critical role in IL-1β–mediated AML progression
Lin, H., Mohammadhosseini, M., McClatchy, J., Villamor-Payà, M., Jeng, S., Bottomly, D., Tsai, C., Posso, C., Jacobson, J., Adey, A., et al. (2024) · Blood · doi:10.1182/blood.2023022079 · Cited by 11
Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect
Murdock, H. M., Ho, V. T., & Garcia, J. S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1359113 · Cited by 11
Persistent postremission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia
Chow, R. D.-W., Velu, P., Deihimi, S., Belman, J., Youn, A., Shah, N., Luger, S. M., Carroll, M. P., Morrissette, J. J. D., & Bowman, R. L. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015149 · Cited by 12
Self-citation
Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia
Rice, W. G., Howell, S. B., Zhang, H., Rastgoo, N., Local, A., Kurtz, S. E., Lo, P., Bottomly, D., Wilmot, B., McWeeney, S. K., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0832 · Cited by 11
Mutations predictive of hyperactive Ras signaling correlate with inferior survival across high-risk pediatric acute leukemia
Ney, G. M., Anderson, B., Bender, J. D., Kumar‐Sinha, C., Wu, Y., Vats, P., Cieslik, M. P., Robinson, D. R., Li, Q., Chinnaiyan, A. M., et al. (2020) · Translational Pediatrics · doi:10.21037/tp.2019.12.03 · Cited by 9
Time to Move to the Single-Cell Level: Applications of Single-Cell Multi-Omics to Hematological Malignancies and Waldenström’s Macroglobulinemia—A Particularly Heterogeneous Lymphoma
García‐Sánz, R., & Jiménez, C. (2021) · Cancers · doi:10.3390/cancers13071541 · Cited by 11
The contribution of single-cell analysis of acute leukemia in the therapeutic strategy
Madaci, L., Colle, J., Venton, G., Farnault, L., Loriod, B., & Costello, R. T. (2021) · Biomarker Research · doi:10.1186/s40364-021-00300-0 · Cited by 10
The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib
Joshi, S. K., Pittsenbarger, J., Kennedy, V. E., Peretz, C. A. C., Perl, A. E., Smith, C. C., Tyner, J. W., Druker, B. J., & Traer, E. A. (2023) · American Journal of Hematology · doi:10.1002/ajh.27096 · Cited by 10
Self-citation
Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling Pathways
Li, G., Yao, J., Lu, Z., Yu, L., Chen, Q., Ding, L., Fang, Z., Li, Y., & Xu, B. (2023) · Drugs in R&D · doi:10.1007/s40268-023-00442-6 · Cited by 10
Identification of a Selective FLT3 Inhibitor with Low Activity against VEGFR, FGFR, PDGFR, c‐KIT, and RET Anti‐Targets
Akwata, D., Kempen, A. L., Dayal, N., Brauer, N. R., & Sintim, H. O. (2023) · ChemMedChem · doi:10.1002/cmdc.202300442 · Cited by 10
Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia
Hu, C., Zhang, Y., Yang, J., Xu, Y., Deng, T., Li, Y., Xu, S., Wang, S., & Wang, P. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01729-0 · Cited by 10
Defective ribosome assembly impairs leukemia progression in a murine model of acute myeloid leukemia
Sjövall, D., Ghosh, S., Fernández‐Fuentes, N., Velasco-Hernández, T., Hogmalm, A., Menéndez, P. R., Hansson, J., Guibentif, C., & Jaako, P. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114864 · Cited by 10
Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?
Chaer, F. E., Perissinotti, A. J., Loghavi, S., & Zeidan, A. M. (2024) · Leukemia · doi:10.1038/s41375-024-02458-6 · Cited by 10
From Chemotherapy to Targeted Therapy: Unraveling Resistance in Acute Myeloid Leukemia Through Genetic and Non-Genetic Insights
Cao, S., Wang, Q., & Zhu, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094005 · Cited by 15
The Evolving AML Genomic Landscape: Therapeutic Implications
Horibata, S., Alyateem, G., DeStefano, C. B., & Gottesman, M. M. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009620666200424150321 · Cited by 10
Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia
Canaani, J., Nagar, M., Heering, G., Gefen, C., Yerushalmi, R., Shem‐Tov, N., Volchek, Y., Merkel, D. G., Avigdor, A., Shimoni, A., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27618 · Cited by 10
Self-citation
Cutting Edge Molecular Therapy for Acute Myeloid Leukemia
Miyamoto, K., & Minami, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145114 · Cited by 11
The Promise of Single-cell Technology in Providing New Insights Into the Molecular Heterogeneity and Management of Acute Lymphoblastic Leukemia
Pearson, H. C. L., Hunt, K. V., Trahair, T. N., Lock, R. B., Lee, H. J., & de Bock, C. E. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000734 · Cited by 9
Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD+ acute myeloid leukemia by inhibiting β-catenin activity via the PP2A-GSK3β axis
Jiang, L., Zhao, Y., Liu, F., Huang, Y., Zhang, Y., Yuan, B., Cheng, J., Yan, P., Ni, J., Jiang, Y., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01774-9 · Cited by 10
Concurrent inhibition of p300/CBP and FLT3 enhances cytotoxicity and overcomes resistance in acute myeloid leukemia
Chen, Y., Zhao, Y., Yao, M., Yf, W., Ma, M., Yu, C.-C., Jiang, H., Wu, W., Shen, J., Xu, X., et al. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01479-w · Cited by 9
Role of intratumoral heterogeneity in metastatic progression and drug resistance
Borker, N. S., Sajimon, J., Subhadarshini, S., Aara, R., Jolly, M. K., Prabhu, J. S., & Nair, R. (2025) · Discover Oncology · doi:10.1007/s12672-025-03322-4 · Cited by 9
Advances and unanswered questions in management of acute myeloid leukemia in older adults: A glimpse into the future
Bhatt, V. R. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.02.011 · Cited by 9
Acute Myeloid Leukemia Mutations and Future Mechanistic Target to Overcome Resistance
Uddin, R., Darwish, N. H. E., & Mousa, S. A. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00880-x · Cited by 9
Single-Cell Technologies to Decipher the Immune Microenvironment in Myeloid Neoplasms: Perspectives and Opportunities
Caprioli, C., Nazari, I., Milovanovic, S., & Pelicci, P. G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.796477 · Cited by 9
Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML
Azhar, M., Kincaid, Z., Kesarwani, M., Menke, J., Schwieterman, J., Ansari, S., Reaves, A., Ahmed, A., Shehzad, R., Khan, A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007486 · Cited by 9
Retinoic acid and proteotoxic stress induce AML cell death overcoming stromal cell protection
Liccardo, F., Śniegocka, M., Tito, C., Iaiza, A., Ottone, T., Divona, M., Travaglini, S., Mattei, M., Cicconi, R., Miglietta, S., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02793-z · Cited by 10
Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper
Dennis, M., Copland, M., Kaur, H., Kell, J., Nikolousis, E., Mehta, P., Palanicawandar, R., Potter, V. T., Raj, K. K., Thomas, I., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18369 · Cited by 8
TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax
Tyagi, A., Jaggupilli, A., Ly, S., Yuan, B., El-Dana, F., Hegde, V. L., Anand, V., Kumar, B., Puppala, M., Yin, Z., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02086-6 · Cited by 8
Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Sonowal, H., Rice, W. G., Bejar, R. L., Byun, J., Jung, S. H., Sinha, R. K., & Howell, S. B. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0258 · Cited by 8
Big data and single‐cell sequencing in acute myeloid leukemia research
Zou, Y., Zhang, H., & Hu, H. (2023) · MedComm – Oncology · doi:10.1002/mog2.47 · Cited by 9
Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia
Lap, C. J. G., Abrahim, M. S., & Nassereddine, S. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05545-3 · Cited by 8
Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach
Acha, P., Palomo, L., Fuster‐Tormo, F., Xicoy, B., Mallo, M., Manzanares, A., Grau, J., Marcé, S., Granada, I., Rodríguez‐Luaces, M., et al. (2021) · Cancers · doi:10.3390/cancers13040841 · Cited by 9
Combination of RSK inhibitor LJH-685 and FLT3 inhibitor FF-10101 promoted apoptosis and proliferation inhibition of AML cell lines
Zhang, S., Liu, J., Lu, Z.-Y., Xue, Y.-T., Mu, X.-R., Liu, Y., Cao, J., Li, Z., Li, F., Xu, K.-L., et al. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00703-7 · Cited by 8
Blockade of de novo pyrimidine biosynthesis triggers autophagic degradation of oncoprotein FLT3-ITD in acute myeloid leukemia
Ma, H., Cui, J., Liu, Z., Fang, W., Lu, S., Cao, S., Zhang, Y., Chen, J., Lu, L., Xie, Q., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02848-7 · Cited by 8
Targeting C/EBPα overcomes primary resistance and improves the efficacy of FLT3 inhibitors in acute myeloid leukaemia
Wang, H., Luo, G., Hu, X., Xu, G., Wang, T., Liu, M., Qiu, X., Li, J., Fu, J., Feng, B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37381-4 · Cited by 7
Application and research progress of single cell sequencing technology in leukemia
Xie, D., An, B., Yang, M., Wang, L., Guo, M. Y., Luo, H., Huang, S., & Fa, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1389468 · Cited by 9
Resolving leukemic stem cell heterogeneity and plasticity with single-cell multiomics
Huang, F. Y., Trumpp, A., & Stelmach, P. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2025.07.001 · Cited by 7
Gilteritinib in FLT3‐mutated acute myeloid leukemia: A real‐world Italian experience
Cairoli, R., Castello, L. D., Imbergamo, S., Pierdomenico, E., Papayannidis, C., Borlenghi, E., Vetro, C., Chiusolo, P., Fumagalli, M., Minotti, C., et al. (2025) · Cancer · doi:10.1002/cncr.70055 · Cited by 7
Counter-Therapeutic Strategies for Resistance of FLT3 Inhibitors in Acute Myeloid Leukemia
Song, M.-K. (2025) · Cells · doi:10.3390/cells14191526 · Cited by 7
Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia
Elgamal, O. A., Fobare, S., Vibhute, S. M., Mehmood, A., Vroom, D. C., Johnson, M. L., Stearns, B., Lerma, J. R., Truxall, J., Stahl, E. H., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.173646 · Cited by 7
Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement
Enjeti, A. K., Agarwal, R., Blombery, P. A., Chee, L. C. Y., Chua, C. C., Grigg, A., Hamad, N., Iland, H. J., Lane, S., Perkins, A. C., et al. (2022) · Pathology · doi:10.1016/j.pathol.2022.03.002 · Cited by 7
Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies
Leśniak, M., Lipniarska, J., Majka, P., Lejman, M., & Zawitkowska, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316708 · Cited by 7
Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome
Hughes, C., Gallipoli, P., & Agarwal, R. (2021) · Pathology · doi:10.1016/j.pathol.2021.01.005 · Cited by 9
Strategies for the treatment of acute myeloid leukemia with FLT3 mutations: a patent review
Górecki, L., Řezníčková, E., Kryštof, V., Řezáčová, M., Čečková, M., & Korábečný, J. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2446224 · Cited by 6
Discovery of a Novel MNK Inhibitor (NSP-1047) with In Vivo Anti-acute Myeloid Leukemia Activity
Li, B., Xia, S., Zhang, K., Huang, Q., Chen, Q. K., Wang, J., Wu, D., Zhang, J., Zou, Y., & Zhang, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00504 · Cited by 6
Real-World Outcomes in FLT3-ITD Mutated Acute Myeloid Leukemia: Impact of NPM1 Mutations and Allogeneic Transplantation in a Retrospective Unicentric Cohort
Vecchio, V., Duminuco, A., Leotta, S., Mauro, E., Maugeri, C., Parisi, M. S., Fiumara, P. F., Raimondo, F. D., Palumbo, G. A., Gozzo, L., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145110 · Cited by 6
Cytomolecular Mechanisms of Relapse and Post‐Relapse Outcomes After Frontline FLT3 Inhibitor‐Based Therapy in FLT3 ‐Mutated AML
Arora, S., Loghavi, S., Daver, N. G., Ravandi, F., Dinardo, C. D., Kadia, T. M., Borthakur, G. M., Jabbour, E. J., Yilmaz, M. E., Issa, G. C., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.70053 · Cited by 6
Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide
Jen, W., Lachowiez, C. A., Marvin‐Peek, J., Altman, J. K., Yilmaz, M. E., Garcia, J. S., Abaza, Y., Short, N. J., Zeidner, J. F., Daver, N. G., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01429-z · Cited by 6
PROTACs: Walking through hematological malignancies
Malhab, L. J. B., AlSafar, H. S., Ibrahim, S. M., & Rahmani, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1086946 · Cited by 6
Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?
Wei, A. H., & Roberts, A. W. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0575 · Cited by 6
Understanding FLT3 Inhibitor Resistance to Rationalize Combinatorial AML Therapies
Shastri, A., Gonzalez‐Lugo, J. D., & Verma, A. K. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0210 · Cited by 6
Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours
Molica, M., & Perrone, S. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2140137 · Cited by 6
Augmenting Venetoclax Activity Through Signal Transduction in AML
Bouligny, I. M., Maher, K. R., & Grant, S. (2023) · Journal of Cellular Signaling · doi:10.33696/signaling.4.085 · Cited by 7
Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation
Chen, P., Huang, B. J., Harris, M., Boone, C. D., Wang, W., Carias, H., Mesiona, B., Mavrici, D., Kohler, A. C., Bollag, G. E., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.168445 · Cited by 6
Reconciling the Gap between Medications and their Potential Leads: The Role of Marine Metabolites in the Discovery of New Anticancer Drugs: A Comprehensive Review
Thaman, J., Pal, R. S., Chaitanya, M., Yanadaiah, P., Prabha, T., Sharma, S., Amoateng, P., Arora, S., Ponnusankar, S., Pandey, P., et al. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128272025231106071447 · Cited by 6
The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases
Yu, G.-P., Zhang, W., Basyal, M., Nishida, Y., Mizumo, H., Ly, C., Zhang, H., Rice, W. G., & Andreeff, M. (2024) · Leukemia and Lymphoma · doi:10.1080/10428194.2024.2364839 · Cited by 5
Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients
Reed, D. R., Sen, J. M., Pierce, E. J., Elsarrag, R. Z., & Keng, M. K. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220918006 · Cited by 6
Single-Cell Sequencing: Biological Insight and Potential Clinical Implications in Pediatric Leukemia
Alpár, D., Egyed, B., Bödör, C., & Kovács, G. (2021) · Cancers · doi:10.3390/cancers13225658 · Cited by 6
Current Approaches to Transplantation for FLT3-ITD AML
Hunter, B. D., & Chen, Y. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00558-5 · Cited by 6
Mitochondrial determinants of response and resistance to venetoclax plus cytarabine duplet therapy in acute myeloid leukemiaPreprint
Bosc, C., Gadaud, N., Bousard, A., Sabatier, M., Cognet, G., Saland, E., Farge, T., Boët, E., Gotanègre, M., Aroua, N., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.17.253856 · Cited by 6
Mechanisms of Resistance to Targeted Therapies in AML
Jones, M. F., & Smith, C. C. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062822-025055 · Cited by 5
Self-citation
Translational control of leukemic metabolism and disease progression
Mercier, F., Gife, V., Aloyz, R. S., & Hulea, L. (2025) · Trends in Cell Biology · doi:10.1016/j.tcb.2025.04.006 · Cited by 6
Acute myeloid leukemia drug resistance: targetable nodes and the clinical trajectory of small-molecule inhibitors
Zhang, X., Peng, Y., Tian, Y., Chen, S., Jia, Y., Liu, M., & Li, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1696229 · Cited by 5
Genomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia
Ribeiro, S., Eiring, A. M., & Khorashad, J. S. (2021) · Cancers · doi:10.3390/cancers13205055 · Cited by 5
Single cell proteogenomic sequencing identifies a relapse‐fated AML subclone carrying FLT3‐ITD with CN‐LOH at chr13q
Kim, T., Lee, H., Capo‐Chichi, J., Chang, M. H., Yoo, Y. S., Basi, G., Ketela, T., Smith, A. C., Tierens, A. M., Zhang, Z., et al. (2022) · eJHaem · doi:10.1002/jha2.390 · Cited by 4
The magnitude of CXCR4 signaling regulates resistance to quizartinib in FLT3/ITD+ cells via RUNX1
Fukuda, S., Matsuda, N., Shoji, T., Onishi, C., Hirade, T., Taketani, T., & Pelus, L. M. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106983 · Cited by 5
N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants
Wang, X., DeFilippis, R. A., Leung, Y., Shah, N. P., & Li, H. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106966 · Cited by 5
Self-citation
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets
Bruno, S., Borsi, E., Patuelli, A., Bandini, L., Mancini, M., Forte, D., Nanni, J., Barone, M., Grassi, A., Cristiano, G., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810002 · Cited by 5
Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation
Ballesta‐López, O., Solana‐Altabella, A., Megías‐Vericat, J. E., Martínez‐Cuadrón, D., & Montesinos, P. (2020) · Future Oncology · doi:10.2217/fon-2020-0700 · Cited by 5
MLL-menin and FLT3 inhibitors team up for AML
Perl, A. E. (2020) · Blood · doi:10.1182/blood.2020007671 · Cited by 5
Self-citation
Current and Emerging Therapies for Acute Myeloid Leukemia
Ball, B. J., Mei, M. G., Otoukesh, S., & Stein, A. S. (2021) · Cancer treatment and research · doi:10.1007/978-3-030-78311-2_4 · Cited by 5
Emergence of BCR-ABL1 (p190) in Acute Myeloid Leukemia Post-Gilteritinib Therapy
Kim, H., Kim, H., & Kim, H. (2023) · Annals of Laboratory Medicine · doi:10.3343/alm.2023.43.4.386 · Cited by 5
FLT3 Inhibition in Acute Myeloid Leukemia
Smith, C. C. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(20)30441-9 · Cited by 5
Self-citation
The beginning of a new therapeutic era in acute myeloid leukemia
Récher, C. (2021) · eJHaem · doi:10.1002/jha2.252 · Cited by 8
optima: an open-source R package for the Tapestri platform for integrative single cell multiomics data analysis
Pei, D., Griffard-Smith, R., Yellapu, N. K., Nissen, E., & Koestler, D. C. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad611 · Cited by 4
Development of Dual FLT3 and CHK1 PROTACs for the Treatment of AML
Lian, X., Gao, Y., Du, W., Xu, C., Dong, X., Che, J., Zhou, Y., Li, J., & Liu, T. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02332 · Cited by 4
Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy
Turkalj, S., Stoilova, B., Groom, A., Radtke, F. A., Mecklenbrauck, R., Jakobsen, N. A., Lachowiez, C. A., Metzner, M., Usukhbayar, B., Salazar, M. A., et al. (2025) · Blood · doi:10.1182/blood.2024027948 · Cited by 8
Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient
García‐Álvarez, M., Yeguas, A., Jiménez, C., Medina, A., González‐Calle, V., Hernández-Ruano, M., Maldonado, R., Aires‐Mejía, I., Casquero, C., Sánchez-Villares, I., et al. (2023) · Biomedicines · doi:10.3390/biomedicines12010066 · Cited by 4
LSP1 promotes the progression of acute myelogenous leukemia by regulating KSR/ERK signaling pathway and cell migration
Tan, L., Gui, X., Li, B., Hu, X., & Wang, Y. (2024) · Hematology · doi:10.1080/16078454.2024.2330285 · Cited by 4
Alkynyl nicotinamides show antileukemic activity in drug-resistant acute myeloid leukemia
Ramdas, B., Dayal, N., Pandey, R., Larocque, E. A., Kanumuri, R., Pasupuleti, S. K., Liu, S., Kanellopoulou, C., Chu, E. F. Y., Mohallem, R., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci169245 · Cited by 4
Molecular and modular intricacies of precision oncology
Chhabra, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1476494 · Cited by 5
Single-cell sequencing applications in acute myeloid leukemia
Lecornec, N., Duchmann, M., & Itzykson, R. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2422833 · Cited by 4
SNACS: a tool for demultiplexing single-cell DNA sequencing data
Kennedy, V. E., Roy, R., Peretz, C. A. C., Koh, A., Tran, E., Smith, C. C., & Olshen, A. B. (2025) · Bioinformatics · doi:10.1093/bioinformatics/btaf265 · Cited by 4
Self-citation
Transcriptional profiling directs the classification of acute leukemias of ambiguous lineage into AML, B‐ALL, or T‐ALL
Mulet‐Lazaro, R., Sijs‐Szabó, A., Hoogenboezem, R. M., van Herk, S., Exalto, C., Koenders, J. E., Hoogeveen, P. G., Kavelaars, F. G., Schelen, A. M., van den Ancker, W., et al. (2025) · HemaSphere · doi:10.1002/hem3.70195 · Cited by 4
The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents
Park, H. S., Son, B. R., Shin, K. S., Byeon, S., Kim, H. K., Yang, Y., Jeong, Y., Han, H. S., Lee, K. H., & Kwon, J. (2021) · Acta Haematologica · doi:10.1159/000516793 · Cited by 4
Gilteritinib‐based combination therapy in adult relapsed/refractory FLT3 ‐mutated acute myeloid leukaemia
Chen, N., Pan, J., Zhou, Y., Mao, L., Lou, Y., Qian, J., Xu, G., Wei, J., Zhou, D., Shou, L., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.19182 · Cited by 4
RAS pathway activation drives clonal selection and monocytic differentiation in FLT3 and BCL2 inhibitor resistancePreprint
Kennedy, V. E., Peretz, C. A. C., Walia, A., Chyla, B., Sun, Y., Hill, J. E., Tran, E., Koh, A., Ferng, T. T., Pintar, S. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.02.636108 · Cited by 4
Self-citation
A revised prognostic model for patients with acute myeloid leukemia and first relapse
Maas, N., Breems, D. A., Klerk, C. P. W., Pabst, T., Gradowska, P. L., Thomas, A., Biemond, B. J., Kuball, J. H. E., van Elssen, C. H. M. J., Visser, O. J., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025015797 · Cited by 3
Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors
Chatterjee, A., Ali, M. K. M., Bailey, C. M., Liu, Y., Small, D., Smith, C. C., Traer, E. A., Wang, Y., Silvestri, G., & Baer, M. R. (2026) · Leukemia · doi:10.1038/s41375-026-02982-7 · Cited by 2
Self-citation
How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to Know
Perrone, S., Tresoldi, C., Rigamonti, S., Molica, M., Zhdanovskaya, N., & Cicconi, L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248681 · Cited by 3
Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3 -mutated AML
Short, N. J., Kantarjian, H. M., Daver, N. G., Azevedo, R. S., Karrar, O. S., Dinardo, C. D., Kadia, T. M., Yilmaz, M. E., Maroun, M., Hachem, M. C. R., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026019841 · Cited by 3
Single cell sequencing in acute myeloid leukemia: Linking genotype to functional phenotype for precision risk stratification and treatment decisions
Anandappa, A. J., Xiao, W., & Miles, L. A. (2026) · Human Pathology · doi:10.1016/j.humpath.2026.106174 · Cited by 3
FLT3 and IDH1/2 Inhibitors for Acute Myeloid Leukemia: Focused Clinical Narrative Review of Forthcoming Drugs from an Indian Context
Singh, S., Jain, K., Singh, J., Garg, N., & Arora, A. (2024) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0044-1779621 · Cited by 3
Rat Sarcoma Virus Family Genes in Acute Myeloid Leukemia: Pathogenetic and Clinical Implications
Khattab, S., Berisha, A., Baran, N., & Piccaluga, P. P. (2025) · Biomedicines · doi:10.3390/biomedicines13010202 · Cited by 4
Integration of CRISPR‐Cas9 screens and multi‐omics profiling reveals chromodomain helicase DNA binding protein 7‐angiopoietin‐1 as a novel multidrug resistance axis in acute myeloid leukemia
Yang, D., Zhang, T., Yang, Y., Zhang, D., Zhou, Z., Wang, N., Fan, J., Xu, C., Fang, Y., Kang, L., et al. (2025) · Interdisciplinary medicine · doi:10.1002/inmd.70053 · Cited by 3
Prognostic mutation constellations in acute myeloid leukaemia and myelodysplastic syndrome
Iacobucci, I., & Mullighan, C. G. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000629 · Cited by 3

Authors: McMahon, C. M., Ferng, T., Canaani, J., Wang, E. S., Morrissette, J. J. D., Eastburn, D. J., Pellegrino, M., Durruthy-Durruthy, R., Watt, C. D., Asthana, S., Lasater, E. A., DeFilippis, R., Peretz, C. A. C., McGary, L. H. F., Deihimi, S., Logan, A. C., Luger, S. M., Shah, N. P., Carroll, M., Smith, C. C., & Perl, A. E.
Affiliations: University of Pennsylvania (US)
University of California, San Francisco (US)
Tel Aviv University (IL)
Roswell Park Comprehensive Cancer Center (US)
Mission Bio (United States) (US)
United States Department of Veterans Affairs (US)
ORCID: McMahon, Christine M.
Ferng, Timothy
Canaani, Jonathan
Wang, Eunice S.
Morrissette, Jennifer J.D.
Eastburn, Dennis J.
Pellegrino, Maurizio
DeFilippis, RosaAnna
Peretz, Cheryl A.C.
McGary, Lisa H.F.
Logan, Aaron C.
Luger, Selina M.
Shah, Neil P.
Carroll, Martin
Smith, Catherine C.
Perl, Alexander E.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2019-08-01
Volume: 9
Issue: 8
Pages: 1050-1063
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-18-1453
PMC: PMC11994087
OpenAlex: W2946259536
Cited by: 446
References: 35
Citations by year: 2026: 35 · 2025: 55 · 2024: 56 · 2023: 62 · 2022: 91 · 2021: 61 · 2020: 68 · 2019: 16
FWCI: 41.51
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: HHS | NIH | National Center for Advancing Translational SciencesHHS | NIH | National Center for Advancing Translational Sciences (NCATS) (TL1TR001880)
American Society of Clinical OncologyAmerican Society of Clinical Oncology (ASCO)
HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (R21 CA198621, R01 CA198089, R01 CA166616, K08 CA187577)
Damon Runyon Cancer Research FoundationDamon Runyon Cancer Research Foundation (Damon Runyon) (CI-99-18)
Biff Ruttenberg Foundation
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
Keywords: acute myeloid leukemia, FLT3 mutation, gilteritinib, FLT3 inhibitor resistance, clonal selection, clonal evolution, NRAS mutation, KRAS mutation, BCR-ABL fusion gene, tyrosine kinase inhibitor resistance, single-cell DNA sequencing
MeSH terms: Adult, Aged, Aged, 80 and over, Aniline Compounds, Female, Humans, Male, Middle Aged, Mutation, Pyrazines, Signal Transduction, Leukemia, Myeloid, Acute, ras Proteins, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, fms-Like Tyrosine Kinase 3, Young Adult, Single-Cell Analysis, High-Throughput Nucleotide Sequencing, Clonal Evolution

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks